NCT01998503View on ClinicalTrials.gov

Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis

PHASE3CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

June 30, 2013

Study Completion Date

August 31, 2013

Conditions
Amyloidosis
Interventions
DRUG

Bortezomib

DRUG

dexamethasone

Given orally

BIOLOGICAL

filgrastim

Given subcutaneous

PROCEDURE

autologous hematopoietic stem cell transplantation (ASCT)

Given on day 0

DRUG

Melphalan

Trial Locations (1)

210002

Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing

All Listed Sponsors
lead

Nanjing University School of Medicine

OTHER

NCT01998503 - Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis | Biotech Hunter | Biotech Hunter